Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Annual General Shareholders' Meeting of May 10, 2017
- Shareholders' approval of the financial statements for 2016 -
- Dividend of €2.96 per share payable as of May 18, 2017 -
- Board Composition: renewal and appointments -
Paris, France - May 10, 2017 - The Combined General Shareholders' Meeting of Sanofi was held today at the Palais des Congrès in Paris under the chairmanship of Serge Weinberg. All resolutions submitted to the vote were adopted by its shareholders.
The shareholders approved, among other resolutions, the individual Company and consolidated financial statements for the year 2016. At the General Meeting, shareholders decided the distribution of a cash dividend in the amount of € 2.96 per share with payment as of May 18, 2017.
The General Meeting also renewed as Director Fabienne Lecorvaisier and approved the appointment of Bernard Charlès and Melanie Lee as independent Directors, for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year 2020.
Following the General Meeting, the new Board of Directors is comprised of 14 members, of whom six are women. A large majority of the Board's Directors is independent
- Serge Weinberg*, Chairman of the Board of Directors
- Olivier Brandicourt, Chief Executive Officer
- Laurent Attal
- Robert Castaigne*
- Bernard Charlès*
- Claudie Haigneré*
- Patrick Kron*
- Fabienne Lecorvaisier*
- Melanie Lee*
- Suet-Fern Lee*
- Christian Mulliez
- Carole Piwnica*
- Diane Souza*
- Thomas Südhof*
The composition of the committees remains unchanged.
The voting results will be available on the Company's website (www.sanofi.com) in the coming days.
The audiocast of the Annual General Shareholder Meeting is available on the Company's website (www.sanofi.com).
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Contacts:
| Relations Presse Laurence Bollack + (33) 1 53 77 46 46 [email protected] | Relations Investisseurs George Grofik + (33) 1 53 77 45 45 [email protected] |
(* Independent Director)
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/51edbdd2-14e5-4db4-9da7-c2241639ea4c
